In a first-in-human clinical trial, an mRNA-based cancer vaccine for glioblastoma showed promising results by inducing T-cell responses in over three-quarters of patients with an acceptable safety profile. The vaccine was able to generate new immune responses and break through immune tolerance to the tumor. Patients with poor prognosis due to MGMT-unmethylated glioblastoma were included in the study, with no dose-limiting toxicities observed. Preliminary results also showed encouraging CD4+ and CD8+ T cell responses. Other novel therapies for brain tumors also showed positive results in the same session, with experts agreeing on the promising nature of innovative approaches like mRNA vaccines, dendritic cells, and CAR-T cells. The need for further investigation and optimization of combinations and settings was also highlighted.
Source link
‘Encouraging’ Early Data for mRNA Vaccine in Glioblastoma
